Back to Agenda
Optimizing the Transition from Preclinical to Clinical Research
Session Chair(s)
Stella Stergiopoulos, MPH, MS
Director, Health Economic and Outcomes Research
EQRx, United States
This session will highlight strategies for transitioning from nonclinical to early phase drug discovery most efficiently. The first presentation will discuss current industry processes and perceived costs in preclinical and early phase drug development. The second presentation will focus on risk mitigation in early phase studies, while the third presentation will focus on strategies for bridging the gap between preclinical and clinical development.
Learning Objective : Identify and map a common and uniform nonclinical through early stage clinical process, to benchmark cycle time and duration data in order to inform management decision-making; Discuss nonclinical drug development costs.
Speaker(s)
Characterizing the Development Pathway from Preclinical through Early Clinical Drug Development
Stella Stergiopoulos, MPH, MS
EQRx, United States
Director, Health Economic and Outcomes Research
Translational Value of Early Target-based Safety Assessment and Associated Risk Mitigation
Laszlo A. Urban, DrSc, MD, PhD
Novartis Institutes for BioMedical Research, Inc., United States
Global Head, Preclinical Safety Profiling
Opportunities for Achieving Higher Levels of Efficiency in Preclinical Research
Simone Braggio, DrSc
Aptuit, Italy
Director, Drug Design and Discovery
Have an account?